Sight Sciences (SGHT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Financial Performance - For the quarter ended March 2025, Sight Sciences, Inc. reported revenue of $17.51 million, a decrease of 9.1% year-over-year [1] - The earnings per share (EPS) was -$0.28, an improvement from -$0.33 in the same quarter last year [1] - The reported revenue exceeded the Zacks Consensus Estimate of $16.53 million by 5.95% [1] - The company delivered an EPS surprise of 3.45%, with the consensus EPS estimate being -$0.29 [1] Key Metrics - Revenue from Dry Eye was $0.39 million, surpassing the average estimate of $0.23 million, but reflecting a year-over-year decline of 60.9% [4] - Revenue from Surgical Glaucoma was $17.11 million, exceeding the estimated $16.23 million, but down 6.3% compared to the previous year [4] - Gross Profit for Dry Eye was $0.28 million, significantly higher than the two-analyst average estimate of $0.07 million [4] - Gross Profit for Surgical Glaucoma was $14.82 million, also above the estimated $14.09 million by two analysts [4] Stock Performance - Shares of Sight Sciences have returned +21.7% over the past month, outperforming the Zacks S&P 500 composite's +11.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]